Introduction

  • Atrial fibrillation with rapid ventricular response (RVR) is one of the most common tachyarrhythmias in the emergency department and ICU. When it occurs in a patient with heart failure with reduced ejection fraction (HFrEF, left ventricular ejection fraction <40%), the reflexive rate-control agents carry real hazard.
  • The instinctive choice, intravenous diltiazem, is a potent negative inotrope. In a failing ventricle it can precipitate worsening heart failure, hypotension, and cardiogenic shock. The 2023 ACC/AHA/ACCP/HRS atrial fibrillation guideline identifies nondihydropyridine calcium channel blockers (diltiazem, verapamil) as potentially harmful and advises against their use for rate control in HFrEF.
  • Preferred agents balance rate control against inotropy: a cautious intravenous beta-blocker (in the patient who is not overtly decompensated), intravenous digoxin (vagally mediated AV-nodal slowing with no negative inotropy), and intravenous amiodarone reserved for the critically ill or decompensated-HF patient (not one who needs immediate cardioversion) when a beta-blocker and digoxin are ineffective or contraindicated.
  • A nuance worth teaching up front: unlike in sinus-rhythm HFrEF, beta-blockers did not reduce mortality in the pooled AF subgroup in AF with HFrEF (Kotecha 2014): here they are chosen for rate control and hemodynamic tolerability, not for prognosis.
  • This pearl compares the three rate-control options for AF with RVR in HFrEF, summarizes the supporting evidence, and lands on the practical bedside decision, including when the answer is not a drug at all, but synchronized cardioversion.

Clinical Detail

Pharmacology

IV beta-blocker
(metoprolol / esmolol)		IV digoxinIV amiodarone
Typical IV dose (verify local protocol)Metoprolol tartrate 2.5–5 mg IV over 2 min, may repeat every ~5 min (usual cumulative max ~15 mg); or esmolol 0.5 mg/kg load then 50–200 mcg/kg/min infusion (titratable). Ultra-short-acting IV landiolol is used in Japan/EU but is not US-approvedWeight-based load ~8–12 mcg/kg lean body weight: give ~50% initially, then ~25% at 6–8 h intervals ×2, reassessing before each fraction; ~1.5 mg is a typical 24-h maximum, not a routine target. Target a low serum digoxin concentration (0.5–0.9 ng/mL); levels ≥1.2 ng/mL carry excess mortality and risk is highest at new initiation (Ahmed, Lopes)For rate control, load more slowly than the ACLS cardiac-arrest regimen to limit hypotension: e.g., 150–300 mg IV over ~1 h (Clemo used ~240 mg over 1 h in decompensated ICU AF, with heart rate down and blood pressure up), then a maintenance infusion per protocol; continuous ECG/BP monitoring, central access for prolonged infusion
Onset for rate controlMinutesSlow: hours to meaningful AV-nodal effect; not for immediate controlVariable; often hours for meaningful rate control
Mechanism & inotropyβ1 blockade slows AV conduction; negative inotrope and chronotropeIncreases vagal tone → slows AV conduction; mild positive inotrope (an advantage in HFrEF); minimal direct blood-pressure loweringMultichannel (β, Ca, K, Na); AV-nodal slowing; minimal negative inotropy
Key adverse effectsBradycardia, hypotension, worsening HF in decompensation, bronchospasmNarrow therapeutic index / toxicity (nausea, visual changes, bradyarrhythmias, AV block); worsened by hypokalemia, hypomagnesemia, renal impairmentHypotension (infusion-rate related), phlebitis, QT prolongation, bradycardia; long-term thyroid / pulmonary / hepatic toxicity
Cautions & interactionsWithhold in overt decompensation, hypotension, high-degree AV block, or active bronchospasmDose-reduce in renal dysfunction; correct K+/Mg2+; avoid or use caution in marked bradycardia, sick-sinus syndrome, or high-grade AV block without a functioning pacemaker; many drug interactionsRaises digoxin and warfarin levels (reduce digoxin ~50% and follow serum levels; monitor INR); caution in marked bradycardia or high-grade AV block without a pacemaker; may chemically cardiovert AF → weigh thromboembolic risk if AF >48 h and not anticoagulated
Role in AF-RVR with HFrEFReasonable once stabilized / euvolemic, but in AF+HFrEF beta-blockers control rate and did not reduce mortality in the pooled AF subgroup (Kotecha); use IV cautiously in acute decompensationUseful acutely, especially when hypotensive or decompensated; slow onset makes it often an adjunct rather than sole immediate controlReasonable in the critically ill or decompensated-HF patient when other rate-control agents (a beta-blocker, digoxin) are ineffective or contraindicated; not a substitute for cardioversion in the peri-arrest/unstable patient
Avoid: nondihydropyridine calcium channel blockers (diltiazem, verapamil) for rate control in HFrEF (LVEF <40%). Their negative inotropic effect can precipitate decompensation and cardiogenic shock; the 2023 ACC/AHA/ACCP/HRS guideline advises against them, and landmark data (MDPIT) plus some acute studies show harm, though the acute-ED evidence is limited and mixed (see Evidence). Reserve non-DHP CCBs for EF >40%.
First, exclude pre-excitation (WPW): in pre-excited atrial fibrillation, AV-nodal blockers (beta-blockers, digoxin, amiodarone, diltiazem, and verapamil) can accelerate accessory-pathway conduction and precipitate ventricular fibrillation. If the AF is pre-excited: synchronized cardioversion if unstable, and IV procainamide or ibutilide if stable.

Doses shown are common adult examples; always verify against your institution's protocol and the patient's renal/hepatic function and hemodynamics. If the patient is hemodynamically unstable because of the arrhythmia itself, synchronized cardioversion, not an AV-nodal agent, is first-line.

Evidence

StudyDesign / NPopulationOutcomeStrand
Non-dihydropyridine CCB harm in reduced EF
Diltiazem post-MI trial, 1988 (MDPIT)RCT, N=2,466 (post-MI)Pulmonary-congestion subgroup (EF<0.40 similar)Diltiazem → cardiac events HR 1.41 (1.01–1.96) with congestion vs. 0.77 without; interaction P=0.004Reduced-EF harm
Hansen, 1991 (DAVIT I & II)Verapamil post-MI RCTsPost-MI ± heart failureVerapamil reduced mortality in patients without HF (HR 0.64) but showed no benefit in the HF subgroup: the favorable effect is lost (not reversed) when HF is presentChronic post-MI
Hasbrouck & Nguyen, 2022Retrospective, N=125 HFrEF (ED)HFrEF; IV diltiazem vs. metoprololWorsening HF 33% vs. 15% (P=0.019); total adverse events similarAcute
Kapustova et al., 2023Retrospective, N=45 HFrEF (ED)HFrEF; IV diltiazem vs. metoprololNo safety difference; zero hypotensive/bradycardic events; the honest counterpointAcute
Beta-blockers in AF + HFrEF
Kotecha et al., 2014IPD meta-analysis, 18,254 (3,066 AF)HFrEF, stratified by baseline rhythmBeta-blockers cut mortality in sinus rhythm (HR 0.73) but NOT in AF (HR 0.97; interaction P=0.002): in AF+HFrEF the beta-blocker is a rate-control, not a prognostic, choiceConceptual
Nagai et al., 2013 (J-Land)RCT, N=200AF/AFL, LVEF 25–50%IV landiolol vs. digoxin → 2-h HR control 48% vs. 14% (P<0.0001)Acute IV
Sramko et al., 2026 (LARISA)RCT, N=40Acute HF, LVEF<40%IV landiolol+digoxin vs. standard → primary endpoint 80% vs. 20% (P=0.04), faster control. Small; landiolol not US-approved (esmolol = US analog)Acute IV
Digoxin in the HFrEF population
Kotecha et al., 2020 (RATE-AF)RCT, N=160 permanent AF + NYHA≥IIAF with HF symptoms; digoxin vs. bisoprololEqual quality of life; fewer adverse events with digoxin (25% vs. 64%), lower NT-proBNP at 12 moChronic rate control
Khand et al., 2003RCT, N=47Persistent AF + HF, mean LVEF 24%Combination carvedilol+digoxin outperformed either agent alone on rate, LVEF, and symptoms in this small chronic trial, which supports digoxin as an add-on to a beta-blocker (monotherapy remains a guideline option)Chronic rate control
Lopes et al., 2018 (ARISTOTLE)Post-hoc, N=17,897 AFAF (32% on digoxin), incl. HFSerum digoxin ≥1.2 ng/mL → mortality HR 1.56; new initiation HR 1.78; keep levels lowObservational
Amiodarone in the HFrEF population
Delle Karth et al., 2001RCT, N=60 critically illCritically ill AF (not EF-stratified)IV diltiazem vs. amiodarone → hypotension forcing discontinuation 30% vs. 0–5%Acute
Singh et al., 1995 (CHF-STAT)RCT, N=674LVEF ≤40% + heart failureAmiodarone vs. placebo → mortality-neutral (2-yr survival 69.4% vs. 70.8%); LVEF improved; safe in HFrEFChronic safety
Clemo et al., 1998Case series, N=38 (ICU)Destabilizing AF, CCB/BB-refractoryIV amiodarone (~240 mg/1 h) → HR ↓37 bpm AND SBP ↑24 mmHg while diltiazem/digoxin failed and dropped BPAcute mechanism

Rows are tagged by strand (acute rate control vs. chronic HFrEF safety vs. mechanism/observational) so chronic trials are not read as acute evidence. The 2023 guideline advises against non-DHP CCBs in HFrEF; the landmark reduced-EF data (MDPIT harm signal; DAVIT benefit lost in HF) are post-MI, and acute-ED studies split (Hasbrouck harm vs. Hirschy/Kapustova/Compagner no-difference); the caution is mechanism- and landmark-driven, with limited acute-RCT support. Beta-blockers control rate but, unlike in sinus rhythm, do not improve mortality in AF+HFrEF (Kotecha 2014). Digoxin is adjunctive and safest at low serum levels (Khand; Ahmed low-SDC DIG substudy; Lopes) with DIG showing mortality-neutrality and fewer HF hospitalizations. Amiodarone is mortality-neutral in HFrEF (CHF-STAT, SCD-HeFT) and can raise BP while slowing rate acutely (Clemo). Honest gap: no acute-IV RCT of a US-available beta-blocker restricted to confirmed HFrEF (or of amiodarone rate control) exists; the reduced-EF acute data rely on landiolol (non-US).

Conclusions

  • Avoid non-DHP CCBs in HFrEF: the guideline advises against diltiazem/verapamil; the landmark harm data are diltiazem post-MI at EF<0.40 (MDPIT, events HR 1.41) and verapamil's benefit lost in HF (DAVIT, chronic post-MI data). The acute-ED data are mixed, so the caution is mechanism- and landmark-driven. Reserve non-DHP CCBs for EF>40%.
  • Rule out pre-excitation (WPW) first: every AV-nodal agent here (including amiodarone and the CCBs) can precipitate VF in pre-excited AF. Cardiovert if unstable; use IV procainamide or ibutilide if stable.
  • Beta-blockers control rate but did not reduce mortality in the pooled AF+HFrEF subgroup (Kotecha 2014). Use a cautious IV beta-blocker once the patient is not overtly decompensated. The acute-IV reduced-EF RCTs (J-Land, LVEF 25–50%; LARISA, LVEF<40%) used landiolol, which is not US-available; esmolol is the US-available ultra-short-acting β1-blocker, though without equivalent HFrEF RCT evidence.
  • Digoxin is reasonable acutely, especially when hypotensive or decompensated, and is a useful add-on to a beta-blocker (Khand), and an option alone when beta-blockers are contraindicated; it is well tolerated in HFrEF (DIG: mortality-neutral, fewer HF hospitalizations) but keep serum levels low (0.5–0.9 ng/mL; avoid ≥1.2) (Ahmed, Lopes). Amiodarone raises digoxin; reduce the dose ~50%.
  • Amiodarone is mortality-neutral in HFrEF (CHF-STAT, SCD-HeFT) and can raise BP while slowing rate acutely (Clemo, Delle Karth); reserve it for the critically ill or decompensated patient when a beta-blocker and digoxin are ineffective or contraindicated; watch for hypotension and its potential to chemically cardiovert AF (>48 h → thromboembolic risk).
  • Mind the evidence gap and the unstable patient: no acute-IV RCT of a US-available beta-blocker restricted to confirmed HFrEF exists (the reduced-EF acute data use landiolol, and J-Land included EF up to 50%), so individualize. If the patient is hemodynamically unstable because of the arrhythmia itself, the answer is synchronized cardioversion, not an AV-nodal drug. Treat the precipitant and correct potassium and magnesium.

References

  • Micromedex [Electronic version]. Greenwood Village, CO: Truven Health Analytics. Retrieved July 2026, from http://www.micromedexsolutions.com/
  • Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation. Circulation. 2024;149(1):e1-e156. doi:10.1161/CIR.0000000000001193
  • The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med. 1988;319(7):385-392. doi:10.1056/NEJM198808183190701
  • Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation. 1991;83(1):52-60. doi:10.1161/01.cir.83.1.52
  • Hansen JF. Treatment with verapamil after an acute myocardial infarction: review of the Danish studies on verapamil in myocardial infarction (DAVIT I and II). Drugs. 1991;42(Suppl 2):43-53. doi:10.2165/00003495-199100422-00008
  • Hasbrouck M, Nguyen TT. Acute management of atrial fibrillation in congestive heart failure with reduced ejection fraction in the emergency department. Am J Emerg Med. 2022;58:39-42. doi:10.1016/j.ajem.2022.03.058
  • Kapustova K, Phan B, Allison-Aipa T, Choi M. Acute rate control with metoprolol versus diltiazem in atrial fibrillation with heart failure with reduced ejection fraction. Am J Emerg Med. 2023;67:126-129. doi:10.1016/j.ajem.2023.02.019
  • Hirschy R, Ackerbauer KA, Peksa GD, O'Donnell EP, DeMott JM. Metoprolol vs. diltiazem in the acute management of atrial fibrillation in patients with HFrEF. Am J Emerg Med. 2019;37(1):80-84. doi:10.1016/j.ajem.2018.04.062
  • Compagner CT, Wysocki CR, Reich EK, Zimmerman LH, Holzhausen JM. Intravenous metoprolol versus diltiazem for atrial fibrillation with concomitant heart failure. Am J Emerg Med. 2022;62:49-54. doi:10.1016/j.ajem.2022.10.001
  • Jandali MB. Safety of intravenous diltiazem in reduced ejection fraction heart failure with rapid atrial fibrillation. Clin Drug Investig. 2018;38(6):503-508. doi:10.1007/s40261-018-0631-7
  • Kotecha D, Holmes J, Krum H, et al. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet. 2014;384(9961):2235-2243. doi:10.1016/S0140-6736(14)61373-8
  • Nagai R, Kinugawa K, Inoue H, et al. Urgent management of rapid heart rate in patients with atrial fibrillation/flutter and left ventricular dysfunction: comparison of landiolol with digoxin (J-Land Study). Circ J. 2013;77(4):908-916. doi:10.1253/circj.cj-12-1618
  • Sramko M, Benak A, Toman J, et al. Landiolol for rate control in decompensated heart failure due to atrial fibrillation - the LARISA trial. Eur Heart J Acute Cardiovasc Care. 2026. doi:10.1093/ehjacc/zuag027
  • Kotecha D, Bunting KV, Gill SK, et al. Effect of digoxin vs bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life: the RATE-AF randomized clinical trial. JAMA. 2020;324(24):2497-2508. doi:10.1001/jama.2020.23138
  • Khand AU, Rankin AC, Martin W, Taylor J, Gemmell I, Cleland JGF. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol. 2003;42(11):1944-1951. doi:10.1016/j.jacc.2003.07.020
  • Lopes RD, Rordorf R, De Ferrari GM, et al. Digoxin and mortality in patients with atrial fibrillation. J Am Coll Cardiol. 2018;71(10):1063-1074. doi:10.1016/j.jacc.2017.12.060
  • The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336(8):525-533. doi:10.1056/NEJM199702203360801
  • Ahmed A, Pitt B, Rahimtoola SH, et al. Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: a propensity-matched study of the DIG trial. Int J Cardiol. 2007;123(2):138-146. doi:10.1016/j.ijcard.2006.12.001
  • Delle Karth G, Geppert A, Neunteufl T, et al. Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias. Crit Care Med. 2001;29(6):1149-1153. doi:10.1097/00003246-200106000-00011
  • Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia (CHF-STAT). N Engl J Med. 1995;333(2):77-82. doi:10.1056/NEJM199507133330201
  • Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure (SCD-HeFT). N Engl J Med. 2005;352(3):225-237. doi:10.1056/NEJMoa043399
  • Clemo HF, Wood MA, Gilligan DM, Ellenbogen KA. Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias. Am J Cardiol. 1998;81(5):594-598. doi:10.1016/s0002-9149(97)00962-4
Tags:atrial fibrillation rate control HFrEF digoxin amiodarone